Literature DB >> 11343121

ICOS co-stimulatory receptor is essential for T-cell activation and function.

C Dong1, A E Juedes, U A Temann, S Shresta, J P Allison, N H Ruddle, R A Flavell.   

Abstract

T-lymphocyte activation and immune function are regulated by co-stimulatory molecules. CD28, a receptor for B7 gene products, has a chief role in initiating T-cell immune responses. CTLA4, which binds B7 with a higher affinity, is induced after T-cell activation and is involved in downregulating T-cell responses. The inducible co-stimulatory molecule (ICOS), a third member of the CD28/CTLA4 family, is expressed on activated T cells. Its ligand B7H/B7RP-1 is expressed on B cells and in non-immune tissues after injection of lipopolysaccharide into animals. To understand the role of ICOS in T-cell activation and function, we generated and analysed ICOS-deficient mice. Here we show that T-cell activation and proliferation are defective in the absence of ICOS. In addition, ICOS -/- T cells fail to produce interleukin-4 when differentiated in vitro or when primed in vivo. ICOS is required for humoral immune responses after immunization with several antigens. ICOS-/- mice showed greatly enhanced susceptibility to experimental autoimmune encephalomyelitis, indicating that ICOS has a protective role in inflammatory autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343121     DOI: 10.1038/35051100

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  291 in total

Review 1.  Chemokines: the times they are a-changin'.

Authors:  G Márquez; C Martínez-A
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 2.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

3.  ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors.

Authors:  Paul L Bollyky; Rebecca P Wu; Ben A Falk; James D Lord; S Alice Long; Anton Preisinger; Brandon Teng; Gregory E Holt; Nathan E Standifer; Kathleen R Braun; Cindy Fang Xie; Peter L Samuels; Robert B Vernon; John A Gebe; Thomas N Wight; Gerald T Nepom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

4.  Functional plasticity of an antigen-specific memory CD4 T cell population.

Authors:  Mojgan Ahmadzadeh; Donna L Farber
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

Review 5.  CTLA4 gene and autoimmune endocrinopathies: a new marker?

Authors:  F Pociot
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 6.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity.

Authors:  Hiroshi Harada; Alan D Salama; Masayuki Sho; Atsushi Izawa; Sigrid E Sandner; Toshiro Ito; Hisaya Akiba; Hideo Yagita; Arlene H Sharpe; Gordon J Freeman; Mohamed H Sayegh
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

8.  Adaptive resistance: a tumor strategy to evade immune attack.

Authors:  Sheng Yao; Lieping Chen
Journal:  Eur J Immunol       Date:  2013-02-04       Impact factor: 5.532

9.  The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas.

Authors:  Luka de Vos; Ingela Grünwald; Emma Grace Bawden; Jörn Dietrich; Kathrin Scheckenbach; Constanze Wiek; Romina Zarbl; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  Epigenetics       Date:  2020-04-21       Impact factor: 4.528

10.  Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.

Authors:  Derek Ng Tang; Yu Shen; Jingjing Sun; Sijin Wen; Jedd D Wolchok; Jianda Yuan; James P Allison; Padmanee Sharma
Journal:  Cancer Immunol Res       Date:  2013-07-31       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.